For research use only
| Cat No. | ABC-TC0178 |
| Product Type | Human Lung Cancer Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarinoma |
| Product Code | CORL105; COR-L 105 |
COR-L105 Human NSCLC cell line from lung adenocarcinoma; EGFR wild-type; useful for tumor microenvironment, HDACi response, and brain metastasis studies.
COR-L105 is a human large cell lung carcinoma (LCLC) cell line established from a pleural effusion of a male patient with advanced non-small cell lung cancer (NSCLC). Cytogenetically, COR-L105 exhibits a hypotriploid karyotype with chromosomal abnormalities, including structural rearrangements. Functionally, COR-L105 cells may be involved in tumor microenvironment regulation and amino acid metabolic reprogramming due to high expression of genes such as PPBP and SLC6A14. The cell line is EGFR wild-type and KRAS mutant, making it suitable for research on targeted therapies in EGFR-resistant NSCLC. COR-L105 expresses typical markers of large cell carcinoma and shows moderate tumorigenicity in immunodeficient mice. It also retains metabolic and signaling characteristics relevant to the study of cell proliferation, drug resistance, and lung cancer progression.
| Product Code | CORL105; COR-L 105 |
| Species | Human |
| Cat.No | ABC-TC0178 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
COR-L105 can be used to study the mechanism of action of histone deacetylation in the progression of NSCLC. These cells can also be used to evaluate the pro-apoptotic effects of histone deacetylase inhibitors (HDACi) and explore the regulatory network of CIP/KIP family proteins. COR-L105 can also be applied to screen potential drug targets that inhibit blood-brain barrier penetration and provide an experimental model for anti-metastatic therapy.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
